LeMaitre Vascular (LMAT) insider reports 2025 RSU and option equity grants

Rhea-AI Filing Summary

LeMaitre Vascular Inc's chief financial officer reported receiving new equity awards in the company’s stock. On 12/10/2025, the officer acquired 1,177 shares of common stock at a stated price of $0, bringing direct ownership to 2,398 common shares.

The filing also shows a new stock option grant for 7,222 shares with an exercise price of $83.66 and an expiration date of 12/10/2032. The 1,177-share award is structured as restricted stock units that vest 25% on 12/1/2026, with the rest vesting in equal annual installments over the following three years. The option vests over four years at 25% on the first anniversary of the grant date listed, with the balance vesting in equal annual installments over the next three years.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

LeBlanc Dorian Paul

(Last) (First) (Middle)

C/O LEMAITRE VASCULAR, INC.

63 SECOND AVENUE

(Street)

BURLINGTON MA 01803

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
LEMAITRE VASCULAR INC [ LMAT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
12/10/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/10/2025		A		1,177(1)	A	$0	2,398	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$83.66	12/10/2025		A		7,222		12/01/2025(2)	12/10/2032	Common Stock	7,222	$0	7,222	D

Explanation of Responses:

1. Represents a restricted stock unit award that vests on a time-based schedule as follows: 25% of the award vests on 12/1/2026, with the balance vesting in equal annual installments over the remaining three years. This award includes a provision for the withholding of shares by the Issuer to pay the withholding taxes due on each vesting date.

2. This option is exercisable and vests over a four-year period at a rate of 25% on the first anniversary of the date listed in the table, with the balance vesting in equal annual installments over the remaining three years.

	/s/ Laurie A. Churchill, Attorney-in-fact	12/11/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider equity awards did LeMaitre Vascular (LMAT) report in this filing?

The filing reports that LeMaitre Vascular’s chief financial officer received 1,177 shares of common stock as a restricted stock unit award and a stock option covering 7,222 shares at an exercise price of $83.66, both dated 12/10/2025.

How many LeMaitre Vascular shares does the officer own after this transaction?

After the reported transaction, the officer directly beneficially owns 2,398 shares of common stock and 7,222 stock options linked to LeMaitre Vascular shares.

What is the vesting schedule for the 1,177 restricted stock units at LeMaitre Vascular?

The 1,177 restricted stock units vest on a time-based schedule: 25% vest on 12/1/2026, with the remaining 75% vesting in equal annual installments over the following three years. Shares may be withheld to cover tax obligations on each vesting date.

What are the key terms of the new LeMaitre Vascular stock option grant?

The stock option is a right to buy 7,222 shares of common stock at an exercise price of $83.66, with an expiration date of 12/10/2032. It vests over four years, with 25% vesting on the first anniversary of the grant date listed and the remainder vesting in equal annual installments over the next three years.

Does this LeMaitre Vascular insider filing show any stock sales?

No stock sales are reported. The Form shows acquisitions of common stock and options, coded as awards (Transaction Code A) at a stated price of $0, reflecting equity compensation rather than open-market sales.

How are taxes handled for the LeMaitre Vascular restricted stock unit award?

The award includes a provision allowing the issuer to withhold shares on each vesting date to pay the withholding taxes due on the vested restricted stock units.